Case Report
Copyright ©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Hepatol. Dec 27, 2020; 12(12): 1349-1357
Published online Dec 27, 2020. doi: 10.4254/wjh.v12.i12.1349
Successful hepatic resection for recurrent hepatocellular carcinoma after lenvatinib treatment: A case report
Hideki Yokoo, Hiroyuki Takahashi, Masahiro Hagiwara, Hiroyoshi Iwata, Koji Imai, Yoshinori Saito, Naoto Matsuno, Hiroyuki Furukawa
Hideki Yokoo, Hiroyuki Takahashi, Masahiro Hagiwara, Hiroyoshi Iwata, Koji Imai, Naoto Matsuno, Hiroyuki Furukawa, Division of Hepato-Biliary-Pancreatic Surgery and Transplant Surgery, Department of Surgery, Asahikawa Medical University, Asahikawa 078-8510, Hokkaido, Japan
Yoshinori Saito, Department of Gastroenterology, Asahikawa-Kosei General Hospital, Asahikawa 078-8211, Hokkaido, Japan
Author contributions: Yokoo H, Takahashi H, Hagiwara M, Iwata H, and Imai K were the patient’s hepato-biliary-pancreatic surgeons, reviewed the literature, and contributed to manuscript drafting; Yokoo H, Takahashi H, and Saito Y analyzed and interpreted the imaging findings; Matsuno N and Furukawa H were responsible for the revision of the manuscript for important intellectual content; All authors issued final approval for the version to be submitted.
Informed consent statement: Informed written consent was obtained from the patient for publication of this report and any accompanying images.
Conflict-of-interest statement: The authors declare that they have no conflict of interest.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Hideki Yokoo, MD, PhD, Associate Professor, Division of Hepato-Biliary-Pancreatic Surgery and Transplant Surgery, Department of Surgery, Asahikawa Medical University, 2-1 Midorigaoka-Higashi, Asahikawa 078-8510, Hokkaido, Japan. hidekiyokoo@asahikawa-med.ac.jp
Received: July 28, 2020
Peer-review started: July 28, 2020
First decision: September 17, 2020
Revised: September 29, 2020
Accepted: October 21, 2020
Article in press: October 21, 2020
Published online: December 27, 2020
Processing time: 142 Days and 7.9 Hours
Core Tip

Core Tip: We report a case of intrahepatic hepatocellular carcinoma recurrence with rapid growth and sternal bone metastases after initial resection. A second surgery was successfully achieved after lenvatinib administration induced tumor shrinkage. Because the patient had bone metastases, multidisciplinary therapy, postoperative radiation therapy, and lenvatinib administration were performed, and the patient remains alive at 1 year postoperatively. In this case, lenvatinib induced a partial response for rapid growth of recurrent hepatocellular carcinoma with bone metastases, and conversion to surgery was successfully achieved for the purpose of controlling the intrahepatic lesion for the first time.